by McDermott + Bull | Feb 16, 2023 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden
In 2022, we saw a significant increase in the number of deals by private equity and venture capital firms within the life sciences, medical, and healthcare sectors. This all points toward positive growth, but the biggest challenge PE and VC firms face is seeing a...
by McDermott + Bull | Feb 1, 2023 | Article, Healthcare + Life Sciences Article, Ken Dropiewski
MEDTECH + LIFE SCIENCES OUTLOOK IN 2023 2022 was an interesting year, to say the least. It was the tale of two markets. After the extremely volatile years of 2020 and 2021, no one could have predicted the sheer amount of momentum that lay ahead in 2022. The economy...
by McDermott + Bull | Nov 22, 2022 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden, Jessica Combs
2022 has been an interesting year for life sciences and executive search. We have finally been able to attend in-person conferences and events without the looming fear of the COVID-19 pandemic hanging over our heads. In October, Jessica Combs and I attended the...
by McDermott + Bull | Jul 25, 2022 | Article, Garrett Lipus, Healthcare + Life Sciences Article, Lipus
RECENT ACTIVITY IN THE HEALTHCARE INDUSTRY Private equity healthcare services’ activity levels reached record highs in 2021 and have remained robust throughout the first half of 2022. Of the 105 healthcare services comps, the median enterprise value or EBITDA...
by McDermott + Bull | Feb 3, 2022 | Article, Healthcare + Life Sciences Article, Ken Dropiewski
LIFE SCIENCES + HEALTHCARE OUTLOOK IN 2022 When the J.P. Morgan Healthcare Conference took place last January, I skipped it, optimistically thinking that things would be different and safer the following year. Shortly before this year’s conference, it was announced...
by McDermott + Bull | Dec 13, 2021 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden
Ringing in the New Year As we slowly emerge from the pandemic, we are beginning to see a bright spot in the future of the life sciences industry and wider global economy. From what I can gather, there is a collective and anticipatory sigh of relief that this will all...
